Does Nintedanib Benefit Certain Subgroups of IPF Patients More than Others? An Analysis of the Data from the INPULSIS Trials
Dr. Nitin Seam talks with Drs. Ulrich Costabel and Athol Wells about idiopathic pulmonary fibrosis and which patients may benefit from nintedanib treatment. They discuss the INPULSIS trials and Dr. Costabel's article in the January 15 issue of AJRCCM.
